Concerning prognostic signatures, work from others reported EpCAM and SLUG [40] as well as a 75-gene list as prognostic biomarker of HNSCC recurrence including molecular determinants of EMT and NF-κB activation for therapeutic intervention [41]. This evidence concerns the gene EPCAM and head and neck squamous cell carcinoma.